Navigation Links
Particle Sciences and HORIBA Instruments Form Strategic Relationship
Date:2/7/2011

BETHLEHEM, Pa., Feb. 7, 2011 /PRNewswire/ -- Particle Sciences, Inc., a leading pharmaceutical CRO, is pleased to announce the establishment of a strategic alliance with HORIBA Instruments of Irvine, CA, which is the U.S. sales and marketing division of HORIBA Limited of Kyoto, Japan.  This alliance assures that both client bases are provided with a total solution, combining the most up-to-date physical characterization tools with operational expertise in a fully GLP/GMP compliant setting.

Under the arrangement, the full array of HORIBA characterization tools will be available at Particle Sciences.  Dr. Robert Lee, Vice President of Pharmaceutical Development at Particle Sciences states, "The need for particle size analysis and physical characterization in general is growing rapidly within this highly regulated environment.  Particle Sciences is a world leader in particulate formulations and drug/device combination products.  We looked for a partner that shared the same commitment to quality and innovation and HORIBA fit the bill."

With this in place, HORIBA clients will have a resource that can both develop and perform characterization under cGLPs and cGMPs.  According to Dr. Mike Pohl, HORIBA's Vice President, "Our client base ranges from startups to the largest multinational Pharma and Biotech companies.  For a variety of reasons, we are often asked if we can recommend a site familiar with pharmaceutical development at which they could have work performed.  We have worked with Particle Sciences for some time and have been impressed with their facility and their team.  By entering into this relationship, we can ensure that our clients not only gain access to the most advanced technology, but also that the operators are highly trained to use the instruments to their fullest capability."

Dr. Lee adds, "Particle Sciences is committed to remaining one of the premier drug delivery development services providers.  We offer a broad array of drug delivery technologies and routinely work on atypical dosage forms.  It's critical that our analytic and characterization capabilities keep pace with our formulation expertise.  Additionally, as our clients scale to clinical and ultimately commercial processes, we need to ensure the methods we develop are phase appropriate and based on readily available techniques.  HORIBA is the world's largest instrument manufacturer with the most complete product offering and can now provide the level of security our clients deserve."

Dr. Pohl asserts, "Many pharmaceutical customers are located along the East Coast.  The combination of our Edison, NJ headquarters plus the Bethlehem, PA location of Particle Sciences, Inc., gives HORIBA a strong one-two punch to support these customers.  Services ranging from sample analysis, customer support, and full consulting services will now be readily accessible to our customers."

The HORIBA Group of worldwide companies provides an extensive array of instruments and systems for applications ranging from automotive R&D, process and environmental monitoring, in-vitro medical diagnostics, semiconductor manufacturing and metrology, to a broad range of scientific R&D and QC measurements. Proven quality and trustworthy performance have established widespread confidence in the HORIBA Brand.  

Particle Sciences is an integrated provider of drug development services.  Particle Sciences has deep expertise in micro and nano-particulate drug delivery technologies and drug/device combination products with additional specialized capabilities in topical and mucosal drug products.  Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic.  The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania.  Visit www.particlesciences.com, email info@particlesciences.com or contact us at (610) 861- 4701 for information.Contact: Maureen Cochran610-861-4701mcochran@particlesciences.com
'/>"/>

SOURCE Particle Sciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. NC State engineers discover nanoparticles can break on through
2. Particle Sciences sells T-COTE(R) Line of Microfine Titanium Dioxides to Sensient
3. Engineering nanoparticles for maximum strength
4. Altogen Biosystems Launches New Nanoparticle-based In Vivo Transfection Reagent
5. MonoSol Rx and Midatech Group Enter Collaboration Agreement to Unite Nanoparticle and Thin Film Drug Delivery Technologies
6. RVX-208 Data Demonstrates Increase in Functional HDL Particles
7. Surface plasmon resonances of metal nanoparticles in array can have narrower spectral widths
8. Enhancing solar cells with nanoparticles
9. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
10. Nanoparticles double their chances of getting into sticky situations
11. Gold-palladium nanoparticles achieve greener, smarter production of hydrogen peroxide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... TOKYO , June 24, 2016  Regular discussions on ... to take place between the two entities said Poloz. ... in Ottawa , he pointed to the ... and the federal government. ... Poloz said, "Both institutions have common economic goals, why not ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... Seattle, WA (PRWEB) , ... June 23, 2016 ... ... technology, announces the release of its second eBook, “Clinical Trials Patient Recruitment and ... patient recruitment and retention in this eBook by providing practical tips, tools, and ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
Breaking Biology Technology:
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
Breaking Biology News(10 mins):